HBM Holdings's revenue per share for the
six
months ended in Jun. 2024 was HK$0.25.
HBM Holdings's revenue per share for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.76.
Warning Sign:
HBM Holdings Ltd revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue Per Share Growth Rate of HBM Holdings was 32.10% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 14.80% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 100.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for HBM Holdings's Revenue per Share or its related term are showing as below:
HKSE:02142'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 14.8 Med: 45.3 Max: 99.1
Current: 14.8
During the past 6 years, HBM Holdings's highest 3-Year average Revenue Per Share Growth Rate was 99.10% per year. The lowest was 14.80% per year. And the median was 45.30% per year.
HKSE:02142's 3-Year Revenue Growth Rate is ranked better than 67.33% of 759
companies
in the Biotechnology industry
Industry Median: 3.5
vs HKSE:02142: 14.80
HBM Holdings Revenue per Share Historical Data
The historical data trend for HBM Holdings's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of HBM Holdings's Revenue per Share
For the Biotechnology subindustry, HBM Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HBM Holdings's PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HBM Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where HBM Holdings's PS Ratio falls into.
HBM Holdings Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
HBM Holdings's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.76
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HBM Holdings (HKSE:02142) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
HBM Holdings Revenue per Share Related Terms
Thank you for viewing the detailed overview of HBM Holdings's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02142 has been successfully added to your 